Symcel is proud to announce a strategic research collaboration with Johnson and Johnson to accelerate and validate Symcel’s next-generation platform for rapid sterility testing.
Through this collaboration, they aim to push forward technology development, data generation, and regulatory approvals to implement the new Symcel platform.
Symcel is a leader in microbial detection methods powered by biocalorimetry. Their platform is designed to drastically shorten sterility release timelines - long a bottleneck in advanced therapy manufacturing - by providing faster, more reliable results that integrate into manufacturing workflows.
Sterility testing is the most time-consuming step in releasing cell therapies. Current methods can take 7-14 days, delaying access to critical treatments. This collaboration aims to deliver a validated, GMP-compliant test that cuts release time to under 3 days - improving manufacturing efficiency with faster access for patients.
Symcel CEO Dr. Jesper Ericsson comments: “We are very pleased to enter into this collaboration and look forward to seeing the potential of Symcel’s platform reduce the vein-to-vein time within cell and gene therapy manufacturing.”
Learn more about Symcel rapid sterility testing solutions for cell and gene therapies.
